{"entity":{"id":"resolve","kind":"trial","name":"RESOLVE","aka":["RESOLVE ibrutinib pancreatic"],"tldr":"RESOLVE tested the leukaemia drug ibrutinib as a way to reprogramme the immune cells around pancreatic tumours; added to nab-paclitaxel and gemcitabine it shortened the time to progression and cut the chemotherapy patients could tolerate, with no survival gain.","summary":"RESOLVE randomised 424 patients (211 ibrutinib, 213 placebo). After a median follow-up of 25 months, median overall survival was 9.7 against 10.8 months (p 0.3225), progression-free survival was shorter with ibrutinib (5.3 against 6.0 months; p below 0.0001) and response lower (29 against 42 percent; p 0.0058); patients on ibrutinib spent less time on treatment and received lower cumulative doses of every agent. Grade 3 or worse neutropenia was 24 against 35 percent, peripheral sensory neuropathy 17 against 8 percent and anaemia 16 against 17 percent. Seven UK sites took part (Derriford Plymouth, Broomfield Chelmsford, the Christie, Southampton, Clatterbridge, the Royal Marsden Sutton and the Royal Free). The registry figure of 430 exceeds the 424 randomised in the paper by six.","status":"negative","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02436668","url":"https://clinicaltrials.gov/study/NCT02436668"},{"label":"Tempero et al., RESOLVE (Annals of Oncology 2021)","url":"https://doi.org/10.1016/j.annonc.2021.01.070"}],"tags":[],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","kinase-inhibitors"],"targets":["btk"],"drugs":["ibrutinib","gemcitabine-nab-paclitaxel"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":["pancreatic-failed-programmes"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry, 7): Derriford Hospital Plymouth; Broomfield Hospital Chelmsford; The Christie Manchester; Southampton General; Clatterbridge Cancer Centre; Royal Marsden Sutton; Royal Free London."],"nct":"NCT02436668","phase":"3","setting":"Untreated metastatic pancreatic ductal adenocarcinoma at sites in eight countries: ibrutinib 560 mg daily or placebo with nab-paclitaxel plus gemcitabine, double-blind, with overall survival and investigator-assessed progression-free survival as primary endpoints","sponsor":"Pharmacyclics (AbbVie)","result":"Median overall survival 9.7 months with ibrutinib plus nab-paclitaxel and gemcitabine against 10.8 months with placebo (p 0.3225); progression-free survival 5.3 against 6.0 months (p below 0.0001); response 29 against 42 percent.","yearReported":2021,"enrolled":430,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Ibrutinib + nab-paclitaxel + gemcitabine","n":211,"value":9.7},{"name":"Placebo + nab-paclitaxel + gemcitabine","n":213,"value":10.8}],"p":"0.3225","source":"https://doi.org/10.1016/j.annonc.2021.01.070"},{"endpoint":"Progression-free survival (investigator)","primary":true,"unit":"months","arms":[{"name":"Ibrutinib + nab-paclitaxel + gemcitabine","n":211,"value":5.3},{"name":"Placebo + nab-paclitaxel + gemcitabine","n":213,"value":6}],"p":"<0.0001","source":"https://doi.org/10.1016/j.annonc.2021.01.070"}]},"route":"/trials/resolve/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"}],"drug":[{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}],"term":[{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/"}]}}